All News

Both pharmacy groups state that rule should have addressed DIR fees.

Studies indicate a lack of deprescribing is causing physical and fiscal pain to patients. 

Fragmin, a low-molecular-weight heparin dalteparin sodium injection, was approved for symptomatic venous thromboembolism.

Venetoclax, a BCL-2 inhibitor first approved in 2016, is now indicated for chronic lymphocytic leukemia and small lymphocytic lymphoma.

Pete Kreckel discusses how he is always working to improve the workflow in his pharmacy. 

Xellia Pharmaceuticals will manufacture essential antibiotics for Civica Rx.

Approval marks the first anti-PD-L1 therapy combination for RCC.

With tight margins, DIR fees, generic effective rate fees, and the delay in receiving third-party reimbursements, it’s easy to find yourself faced with cash flow pressures.

Suit filed in Connecticut alleges companies conspired to inflate prices on more than 100 generic drugs.

Despite legal restrictions and insufficient regulation, the market for CBD oil is booming. 

Biosimilar guidance provides “clarity” for drug developers.

New indication joins a series of single-agent and combination treatments for various cancers.

As patient needs place greater demands on PCPs, pharmacy is changing - and it means opportunities for new lines of service.

The company is donating enough drugs for 200,000 patients for up to 11 years, but does it make up for the high price of the drug?

A look at common HIPAA mistakes in pharmacies and how to avoid them. 

Brian McCullough, PharmD, BCPS, of Husson University notes some common mistakes pharmacists make with patient privacy and offers some ways to fix them.

Finalized rule is a step toward increasing drug pricing transparency.

Premier is exiting the specialty pharmacy market and selling its ProCare Pharmacy company.

Nearly 12 million pounds of medications collected since the initiative’s inception.

Recent trial shows greater invasive disease-free survival when treated with Kadcyla , (ado-trastuzumab emtansine)

New drug combines dapagliflozin, saxagliptin, and metformin.

Two different versions of tafamadis get the FDA’s nod to treat a rare heart disease. 

New services will start with select pharmacists before expanding to Walgreens team memebers and potentially a nationwide resource.

Tibsovo (ivosidenib) is an isocitrate dehydrogenase1- inhibitor, originally approved in 2018.

First vaccine approved for all four Dengue virus serotypes in children and teens ages 9 through 16, but comes with major restrictions and controversy.

Results from a recent ELLIPSE trial indicate superiority in reducing blood sugar when compared to the placebo.